Related Experiment Video

Updated: Mar 19, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

933

Cardiac Biomarkers and Left Ventricular Hypertrophy in Asymptomatic Hemodialysis Patients

Reneta Yovcheva Koycheva1, Vasil Cholakov1, Jivko Andreev1

  • 1Department of Nephrology, University Hospital "Prof. Dr. Stoyan Kirkovich", Stara Zagora, Bulgaria.

Open Access Macedonian Journal of Medical Sciences
|June 9, 2016
PubMed

Insights

Elevated cardiac biomarkers like hs-cTnT and NT-proBNP are linked to left ventricular hypertrophy (LVH) in hemodialysis patients. These markers may help identify LVH in asymptomatic individuals on dialysis.

Area of Science:

  • Cardiology
  • Nephrology
  • Biomarker Research

Background:

  • Cardiac biomarkers are frequently elevated in dialysis patients, indicating left ventricular dysfunction.
  • Left ventricular hypertrophy (LVH) is common in patients undergoing hemodialysis.
  • The study investigates cardiac biomarkers in relation to LVH in asymptomatic dialysis patients.

Purpose of the Study:

  • To determine plasma levels of high-sensitivity cardiac troponin T (hs-cTnT), NT-proBNP, and hs-CRP.
  • To examine the relationship between these biomarkers and LVH in hemodialysis patients without acute coronary syndrome or heart failure.

Main Methods:

  • 48 hemodialysis patients (26 male, 22 female) were studied.
  • Plasma levels of hs-cTnT, NT-proBNP, and hs-CRP were measured pre- and post-dialysis.
  • Patients were categorized into two groups based on echocardiographic evidence of LVH.

Main Results:

  • All three biomarkers were elevated pre-dialysis, with significant increases post-dialysis using low-flux dialyzers.
  • NT-proBNP showed moderate positive correlation with hs-cTnT and weaker with hs-CRP.
  • Significant differences in hs-cTnT and NT-proBNP levels were observed between patients with and without LVH, but not for hs-CRP.

Conclusions:

  • The study indicates a relationship between hs-cTnT, NT-proBNP, and LVH in asymptomatic hemodialysis patients.
  • These cardiac biomarkers may serve as indicators for LVH in this population.
  • Further research could explore the clinical implications of these findings.
Abstract

Keywords:
C-reactive proteincardiac troponin Themodialysisleft ventricular hypertrophynatriuretic peptide

More Related Videos

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

22.4K
Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery08:17

Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery

Published on: February 20, 2017

15.1K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
640
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
717
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.1K
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
709
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
514